News
Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.
Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.
The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results